Accelerating Access to Critical Therapies for ALS Reauthorization...
To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 aims to extend the current provisions of the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. This act helps patients with Amyotrophic Lateral Sclerosis (ALS) gain quicker access to new treatments. The bill has received bipartisan support and has been introduced and passed through both the House and Senate.
This bill primarily affects individuals diagnosed with ALS and their families, as well as healthcare providers and pharmaceutical companies involved in ALS treatment research and development. By reauthorizing the act, the bill ensures continued support and resources for developing and approving new therapies for ALS, potentially improving patient outcomes and quality of life.
As of the last update, the bill has been passed by both the House and Senate without any amendments. It was received in the Senate on July 23, 2026, and passed in the Senate on September 28, 2026, by a voice vote. The bill's progress through the legislative process highlights its importance and the broad support it has garnered.
